XDA Developers on MSN

I tried 3 no-code Replit and Lovable alternatives, and one of them beats both at their own game

Model choice actually did more work than the tools did ...
Consumer Reports

Which Brands Have the Best Long-Term Car Reliability?

Consumer Reports’ brand ranking for used cars—focused on the reliability of 5- to 10-year-old models—makes it clear that buyers can reduce their risk of car trouble by concentrating on some brands ...
Hackaday

Using 3D Printers To Make Circuit Boards

Custom printed circuit boards have become more and more accessible to the average hobbyist over the last decade. But one problem still remains: your circuits will take at least a couple days to make.
The New York Times

Silicon Valley’s Answer to Declining Male Fertility? Sperm Racing.

A San Francisco biotech start-up races sex cells on tiny tracks. Can an internet joke become a serious business? Credit...Photo illustration by Ricardo Tomás Supported by By Daniel Waite Penny Daniel ...
GameSpot

Nintendo Tells Fans To “Stay Tuned” For Next 3D Mario Game On Switch 2

Compared to previous Nintendo gaming console launches, the Switch 2 is arriving with a very small selection of first-party games. A new 3D Mario game was expected to be revealed during the big April ...
BioSpace

CREATE jumps into CAR T competition with $122M series B

CREATE Medicines is working on a clinical-stage pipeline for cancer, while its autoimmune programs are still in preclinical testing. CAR T specialist CREATE Medicines has raised $122 million to ...
FierceBiotech

Create Medicines fashions $122M fundraise for in vivo CAR-T dreams

While Create’s autoimmune pipeline is entirely preclinical, it has dosed more than 50 patients in trials of its cancer candidates. (iStock / Getty Images Plus) As the wave of in vivo CAR-T hype crests ...
BioSpace

CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology

CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune programming, today announced the closing of its $122 ...
precisionmedicineonline

Create Medicine Raises $122M to Advance In Vivo CAR T-Cell Pipeline

NEW YORK – Create Medicines on Thursday said it raised $122 million in Series B financing to advance its pipeline of oncology and autoimmune in vivo CAR T-cell therapy candidates. The financing was ...
BioPharma Dive

Create Medicines raises $122M to bolster in vivo CAR-T therapies

Cambridge-based Create Medicines announced Thursday it has raised another $122 million to bolster its cell therapy capabilities across cancers and autoimmune conditions. The Series B financing round ...